Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by mitch0frenchon May 25, 2018 10:39am
198 Views
Post# 28080548

RE:RE:The “Right to Try” Drug Bill

RE:RE:The “Right to Try” Drug BillIf this bill pass ,
the futur Phase 3 for ipf 4050 (wonder) must be seen different from that moment.
DIRECT COSTS can be recover
--So the cost of buying OFEV med.for phase3  by PLI can be charged to the patient.
--Direct costs as manufacturing the product can also be charged to the patient.
So the cost of the futur phase 3 trials for all the Bio pharma, those that have done well in phase 1 and 2 product ,can be reduce by a large amount!!!!!!!!!!!...In this way only, this bill can be seen as good.
What happened with Ryplazim is the best example of what this bill can correct!!!!!!!!!!!! 

 
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse